<DOC>
	<DOC>NCT02040116</DOC>
	<brief_summary>The purpose of this study is to evaluate the impact of rapid infusion rituximab on the incidence of infusion-related reactions in patients with Autoimmune Diseases.</brief_summary>
	<brief_title>Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases</brief_title>
	<detailed_description />
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Autoimmune Diseases</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Autoimmune patient at Wake Forest Baptist Health that is eligible for rituximab therapy Tolerate the standard infusion rituximab with ≤ grade 2 hypersensitivity reaction Consent to participate in the rapid infusion study Age ≥ 18 years ≤ 80 years Tolerate the standard infusion rituximab with ≥ grade 3 hypersensitivity reaction Neurocognitive impairment (i.e. dementia, Alzheimers, et al)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Rapid Infusion Rituximab</keyword>
</DOC>